Elevated de novo fatty acid biosynthesis (DNFA) is a hallmark adaptation in many cancers that supports survival, proliferation, and metastasis. Here we elucidate previously unexplored aspects of transcription regulation and clinical relevance of DNFA in melanomas. We show that elevated expression of DNFA genes is characteristic of many tumor types and correlates with poor prognosis. Elevated DNFA gene expression depends on transcription factor SREBP1 in multiple melanoma cell lines. SREBP1 predominantly binds to the transcription start sites of DNFA genes, directly regulating transcription via RNA polymerase II recruitment and productive elongation. We find that SREBP1-regulated DNFA represents an intrinsic survival mechanism in melanoma cells, regardless of proliferative state and oncogenic mutation status. Indeed, malignant melanoma cells exhibit elevated DNFA gene expression after pro-survival signaling pathways are blocked (e.g. by the BRAF inhibitor vemurafenib). Altogether, these results implicate SREBP1 and DNFA enzymes as enticing therapeutic targets in melanomas.
Introduction
Cancer cells characteristically achieve hallmark traits that facilitate proliferation, survival, and metastasis [1] [2] [3] . One hallmark adaptation is de novo fatty acid synthesis (DNFA), metabolic conversion of carbohydrates into lipids via acetyl-CoA and NADPH with the aid of multiple lipogenic enzymes, including ATP citrate lyase (ACLY), acyl-coenzyme A synthetase 2 (ACSS2), acetyl-CoA carboxylase (ACACA), fatty acid synthase (FASN), and stearoyl-CoA desaturase (SCD) 4 . DNFA occurs in cancer cells and certain types of healthy cells 5 . In liver cells, DNFA pathway activity is regulated at the level of DNFA enzyme gene expression in response to dietary lipids (e.g. polyunsaturated fatty acids [6] [7] [8] ), and hormonal cues such as insulin 9 . DNFA is also increased in normal cells and tissues during embryonic development and adipogenesis to satisfy elevated lipid demands during cell proliferation and fat storage processes, respectively 10, 11 . The transcription factor Sterol Regulator Element-Binding Protein 1 (SREBP1) plays a central role in controlling DNFA gene expression, and thus serves as a master regulator of cellular FA/lipid production 12, 13 . There are two major mechanisms involved in SREBP1 regulation: mRNA expression and proteolytic processing 14 . The SREBF1 gene, whose transcription is regulated by insulin and cellular/membrane lipids, encodes a SREBP1 precursor protein embedded in the endoplasmic reticulum membrane through two transmembrane domains [15] [16] [17] . In response to depletion of cellular and membrane lipids, SREBP cleavage-activating protein (SCAP) escorts SREBP1 to the Golgi apparatus, where its active, nuclear form (nSREBP1) is released by Site 1 and Site 2 proteases [18] [19] [20] , allowing nuclear translocation and binding to the promoters of target genes. nSREBP1 activates the transcription of DNFA genes, in concert with other transcription factors LXR 21 , USF1 22 , NFY1 23 and SP1
24
, and co-activators MED15 24 and CREBBP 25 . nSREBP1 also participates in activation of SREBF1 mRNA expression by binding to its own promoter 25 , thus the levels of DNFA mRNAs parallel the changes in SREBF1 expression 12 .
Elevated DNFA has been demonstrated in many tumor types 26 , including breast cancer 27 , prostate cancer 28 , and glioblastoma multiforme 29 . The prevailing thought is that hallmark traits, such as DNFA, arise chiefly as a consequence of pro-survival signaling pathways driven by genetic alterations of oncogenes and tumor suppressors [30] [31] [32] [33] . Supposed dependence of tumor cells on a single oncogenic driver or pathway to sustain proliferation and/or survival has guided the development of targeted cancer therapies 34, 35 . However, in clinical settings, tumors harbor highly diverse genetic alterations, and exhibit stochastic evolution 36 . The prognostic and therapeutic value of driver alterations is therefore frequently limited [37] [38] [39] [40] . Resistance to targeted therapies is common in tumors due to mechanisms related to reactivation or bypass of downstream signaling pathways 41 . It is unclear whether oncogene alterations maintain hallmark traits such as DNFA in malignant tumors. Furthermore, potential interaction between oncogenic drivers and DNFA has not been fully investigated, especially under the selection pressure of targeted therapies.
We show here that elevated expression of SREBP1 target genes (e.g. key DNFA enzymes such as SCD) is significantly associated with poor prognosis in cancers, including melanomas. Our detailed mechanistic analyses reveal that SREBP1 and DNFA play crucial roles in melanoma cell proliferation and survival, as well as resistance to targeted therapies (e.g., the BRAF inhibitor vemurafenib) in melanoma cancer cells.
Results

Elevated mRNA expression of DNFA enzymes is prevalent in many cancers, including malignant melanomas, and has prognostic value
Elevated lipogenic enzyme activities have been reported in colon, breast and prostate cancers [42] [43] [44] . We analyzed the expression of mRNAs encoding the DNFA enzymes SCD, FASN, ACLY and ACSS2 using RNA-Seq data from 30 diverse cancer types in The Cancer Genome Atlas (TCGA) (Fig. 1a, b and Supplementary Fig. 1a, b) . We found that DNFA enzyme expression varies widely among different types of cancers, with melanoma exhibiting among the highest levels of expression. Kaplan-Meier analyses indicate that elevated SCD, FASN and ACLY mRNA expression each correlates with poor prognosis in the skin cancer study group (SKCM) (Fig. 1d , and Supplementary Fig. 1d, f) . Expression of SCD and FASN likewise was significantly elevated in all cancers considered collectively ( Fig. 1c and Supplementary Fig. 1c ), whereas for consideration of SKCM as distinct among cancer types -ACLY was not ( Supplementary Fig. 1e ). Prior reports have described activation of enzymes for both DNFA and cholesterol biosynthesis triggered by oncogenic pathways 45, 46 . However, we observed low expression of HMGCS1 and HMGCR, rate-limiting enzymes in the cholesterol biosynthesis pathway 47 , in melanomas compared to other cancer groups and no prognostic value for their expression (data not shown). Among healthy tissues, skin SCD expression is low ( Supplementary Fig. 2a ); yet among tumor tissues, skin SCD expression is elevated (Fig.  1a ). This contrasts with other cancers such as those derived from the liver, which exhibits relatively high SCD expression among healthy (behind only brain and adipose, Supplementary Fig. 2a ) and tumor tissues (Fig. 1a) alike.
To exclude the possibility that SCD overexpression in melanomas is due to tissue-specific upregulation, we compared SCD expression using normalized RNA-Seq data from the skin cancer group in TCGA and normal skin tissue group in the Genotype-Tissue Expression (GTEx) database. SCD expression is much higher in the cancer group versus normal skin group (Supplementary Fig. 2b ). Moreover, principal component analysis (PCA) shows that skin tumors are distinct from samples of normal skin, based on comparison of expression levels of five DNFA genes ( Supplementary Fig. 2c ). To confirm that DNFA enzyme expression was specific to malignant cells within bulk tumors, we further analyzed single cell RNA-Seq data from melanoma patient samples 48 . High expression of DNFA enzyme genes such as SCD, FASN, and ACACA was confined to malignant cells, with very low expression in healthy adjacent tissue ( Fig. 1e and Supplementary Fig. 2d-g ). BRAF and NRAS mutations, while being well-known as risk factors and drivers of cancer onset, have limited prognostic significance for overall survival of melanoma patients 49 . Consistently, we observed no significant correlation between DNFA enzyme expression and common oncogenic driver mutations in SKCM from TCGA ( Supplementary Fig. 3a-l) .
SREBP1 controls highly active DNFA gene expression in melanoma cells
To test whether SREBP1 drives elevated DNFA enzyme expression in melanoma cells, we depleted the mRNA encoding SREBP1 (SREBF1) with antisense oligonucleotides (ASOs) and siRNAs. We found that depletion of SREBF1 with both siRNA and ASO agents was accompanied by decreasing protein levels of SREBP1 and DNFA enzymes (Fig. 2a) . We confirmed that pooled siRNA and ASO agents effectively depleted SREBP1 protein, both the cytoplasmic precursor form and the mature form in the nucleus (Fig. 2b,  c) . Among six tested ASOs targeting SREBF1, we found that ASO-1 and ASO-4 yielded strong inhibition of SREBP1 protein and DNFA enzyme production in melanoma cells (Fig. 2a, b) . ASO-1 and ASO-4 are more potent than single or pooled siRNAs for SREBF1, as 5 nM of ASOs achieved a similar degree of inhibition on DNFA enzyme production as 50 nM of siRNAs ( Fig. 2a and Supplementary Fig. 4b-f ), even when siRNAs decreased the level of SREBF1 mRNA more than ASOs ( Supplementary Fig. 4a ). Our interpretation is that, other than mRNA degradation mechanism similar to siRNAs, ASOs may engage in steric translation inhibition of the SREBF1 mRNA 50 . We found that ASO-4 inhibits DNFA gene expression commensurately with dosage ( Supplementary Fig. 4g ). We also observed a dose-response relationship of diminished cell viability with increased ASO concentration that was not evident with siRNAs (data not shown).
To investigate various potential activators of DNFA enzyme expression, we depleted SREBF1, SREBF2, and co-activators MED15 and CREBBP with siRNAs, and examined expression of DNFA enzymes across melanoma cell lines HT-144 ( Fig. 2d-e) , A375 (Supplementary Fig. 4i -j) and MEL-JUSO ( Supplementary Fig. 5a-b) . We observed a similar range of mRNA reductions (50%-70%) for most DNFA enzymes after SREBF1 depletion, and lesser reduction after co-activator depletion in the three melanoma cell lines (Fig. 2d, Supplementary Fig. 4i and Supplementary Fig. 5a ). Depletion of coactivators MED15 and CREBBP individually or together has some impact on DNFA gene expression, but to a lesser extent than depletion of SREBF1 ( Supplementary Fig. 4i and Supplementary Fig. 5a ). SREBF2 depletion is more specific for genes in cholesterol biosynthesis ( Supplementary Fig. 4h and Supplementary Fig. 4k ), in line with previous studies in liver 51 . SREBF2 also affected DNFA enzyme expression, especially in combination with SREBF1 depletion (Supplementary Fig. 5a and Supplementary Fig. 5c-d) . The role of SREBF2 in regulation of DNFA enzyme expression may be transitive via SREBF1 52 , since SREBF1 expression decreased after SREBF2 depletion ( Supplementary Fig. 5e ), or it may be acting in a partially redundant manner 53 . Thus, we confirmed the known transcription regulatory role of SREBP1 in controlling DNFA gene expression in multiple melanoma cell lines.
To understand the dynamics of DNFA gene expression, we performed a time course study of DNFA expression in A375 cells cultured under SREBP1-activating conditions (1% ITS medium); as expected, FASN and SCD displayed increased expression at consecutive time points under these conditions ( Supplementary Fig. 5c-f) . SREBF1 depletion by siRNA decreased DNFA gene activation in A375 cells on days 3 and 5, in agreement with the notion that SREBP1 directly regulates expression of DNFA enzyme genes. Next, we evaluated the response to SREBP1 over-expression using transfected plasmids encoding the constitutively active (nuclear) form of SREBP1a (nSREBF1a), nuclear form of SREBP1c (nSREBF1c) or control vector in HT-144 melanoma cells. We observed elevated expression of DNFA enzyme proteins by Western blotting (Fig. 2f) and DNFA genes by RT-qPCR analysis (Fig. 2g-h ) in response to increased expression of both SREBP1a and SREBP1c isoforms. SREBP1c is the predominant isoform in adult organs such as liver and adipose tissues 54 , while SREBP1a is more abundant in proliferating embryonic cells and in cancers. With a longer transactivation domain, SREBP1a interacts more avidly with co-activators and thus exhibits stronger transcription activity than SREBP1c 24, 55 . Consistently, we observed higher expression of DNFA genes after overexpressing SREBP1a than SREBP1c. Our overall interpretation of the results is that SREBP1 is sufficient for highly active DNFA gene expression in melanoma cells, which is in accord with previous published studies in other cancer cell types.
SREBP1 maintains highly active DNFA gene expression through RNAP II recruitment and productive transcription elongation
To further assess the gene regulatory function of SREBP1 in melanoma cells, we carried out RNA-Seq analysis after SREBF1 depletion with pooled siRNAs and individual ASOs in HT-144 cells, followed by principal component analysis (PCA) on RNA-Seq data to characterize the gene expression patterns after SREBF1 depletion. The two principal components in the PCA biplot represent over 70% of the overall gene expression changes ( Fig. 3a and Supplementary Fig. 6a ). SREBF1 and SCD are among the top six contributors to data separation and they align with principal component 2 (PC2) (Fig. 3a) . We found that the major contributors to PC2 were SREBF1 and DNFA genes including FASN and SCD (Supplementary Fig. 6b ). SREBF1 siRNA, ASO-1 and ASO-4 obtained similar vertical separations to all negative controls in PC2, and they all reduced mRNA reads of FASN and SCD compared to negative controls ( Supplementary Fig. 6e-g ). These results indicate that the most profound effects after SREBF1 depletion by both ASO and siRNA are on DNFA genes. ASO-1 has significant lateral separation from ASO-4 and SREBF1 siRNA on principal component 1 (PC1) (Fig. 3a) . We found that changes of SPIRE1 and USP9X expression are the major contributors to PC1 (Supplementary Fig.  6c ) and are only affected by ASO-1 ( Supplementary Fig. 6h, i) . This result indicates that ASO-1 has specific off-target effects on SPIRE1 and USP9X genes. Multiple negative controls grouped together, and ASO-4 is close to SREBF1 siRNA on the PCA biplot, consistent with the result of hierarchical clustering analysis on the same RNA-Seq data ( Supplementary Fig. 6d ). Hence, ASO-4 has similar specificity as pooled SREBF1 siRNAs for SREBF1 depletion.
To assess the overall transcriptome affected by SREBF1 depletion, we examined the differentially expressed genes (DEGs) in the RNA-Seq data (siSREBF1 vs siNegative groups) (Supplementary Fig. 6j ). Using gene-set enrichment analyses (GSEA) with Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and Gene ontology (GO) terms on DEGs, we determined that fatty acid biosynthesis pathway and lipid metabolism pathways are enriched among downregulated genes after SREBF1 depletion (Fig. 3b , and Supplementary Fig. 6k ). Cellular inflammatory response pathways were significantly enriched in upregulated genes after SREBF1 depletion (Fig. 3c, and Supplementary Fig.  6l ), including Toll like receptor and tumor necrosis factor (TNF) signaling pathways that mediate tumor cytotoxicity 56 . We suspect that two major altered programs after SREBF1 depletion -decreased fatty acid biosynthesis activities and enhanced inflammatory response activities -may facilitate cell death in melanomas.
The time course RT-qPCR ( Supplementary Fig. 5c, d ) and RNA-Seq (Fig. 3a) analyses suggest direct regulation by SREBP1 of FASN and SCD expression in melanoma cells. To further elucidate the molecular mechanism of DNFA gene activation in melanoma cells, we used chromatin immunoprecipitation (ChIP)-qPCR analysis to detect occupancy of SREBP1 and RNA polymerase II (RNAP II), and a histone mark of transcription elongation (H3K36me3) 57 on DNFA genes. SREBP1 depletion by ASO-4 treatment diminished SREBP1, RNAP II and H3K36me3 signals at the SCD promoter ( Fig. 3d-f) . We observed similar results (albeit with smaller magnitude) for FASN ( Supplementary  Fig. 7a-c) . These ChIP-qPCR results together with the RNA-Seq data in Supplementary  Fig. 6e -g suggest that removal of SREBP1 at DNFA promoters inhibits transcription activity and mRNA production.
To define the molecular action of SREBP1 at DNFA gene promoters in melanoma cells, we performed ChIP-qPCR analyses in SREBP1-activating (1% ITS medium, no lipids) and SREBP1-repressing (10% FBS medium, with lipids) conditions. We found that 1% ITS medium dramatically increased SREBP1 occupancy at the transcription start sites (TSS) of SCD (Fig. 3g) and FASN (Supplementary Fig. 7f ) in HT-144 cells. The strong RNAP II binding peaks at TSS of SCD and FASN in both 10% FBS and 1% ITS culture conditions ( Fig. 3h and Supplementary Fig. 7g ) indicate promoter-proximal pausing of RNAP II 58 . Furthermore, culturing cells in 1% ITS medium increased the occupancy of actively elongating RNAP II (RNAP II S2P) ( Supplementary Fig. 7d , i), but not poised RNAP II (RNAP II S5P) 59 ( Supplementary Fig. 7e , j), at the TSS as well as the gene body of both SCD and FASN genes. Accordingly, levels of the H3K36me3 histone mark, which is associated with transcription elongation, were increased across both genes in cells cultured in SREBP1-activating medium ( Fig. 3i and Supplementary Fig. 7h ). These results suggest that SREBP1 binding at promoters near the TSS associates with RNAP II recruitment and productive transcription elongation on DNFA genes.
To further explore the occupancy of SREBP1 on DNFA genes in cancers, we analyzed public ChIP-Seq data for SREBP1 from lung cancer, breast cancer and chronic myeloid leukemia (CML) cell lines. ChIP-Seq peaks primarily localize at the proximal promoter regions around transcription start sites ( Supplementary Fig. 8a-b) . De novo motif sequences identified from SREBP1 ChIP-Seq peaks match the known SREBP1 binding motif ( Supplementary Fig. 8c ). We determined the overlapping genes among DEGs in our RNA-Seq data and public SREBP1 ChIP-Seq data from A549 and MCF7 cell lines ( Supplementary Fig. 8d ), because of high DNFA gene expression in lung and breast cancers (Fig. 1a) . We reasoned that the overlapping genes are likely regulated directly by SREBP1, and performed functional network analysis on this subset. This analysis revealed genes in the PI3K/AKT pathway and the RNAP II elongation complex, in addition to the expected DNFA pathways ( Supplementary Fig. 8e ). We then performed GSEA on the overlapping genes using expression changes from the RNA-Seq data. Our results show that lipid metabolism pathways are significantly enriched in the overlapping gene set that is downregulated after SREBP1 depletion ( Supplementary Fig. 8f ), confirming SREBP1 as a direct activator of DNFA genes. Although inflammatory response pathways were significantly upregulated in DEGs from RNA-Seq analysis, they seem not to be direct targets of SREBP1 ( Supplementary Fig. 8g ). We suspect downregulation of DNFA pathways may change the homeostasis of cellular fatty acids and exert further impact on inflammatory response pathways as well as cell death 60 .
Melanoma cells exhibit continued and elevated DNFA gene expression after oncogenic signaling blockade with the BRAF inhibitor vemurafenib
To evaluate whether melanoma cells rely on DNFA for cell proliferation and survival, we cultured melanoma cells in the 1% ITS medium, using insulin as a growth factor to stimulate proliferation while constraining cellular lipid availability to DNFA output. The metastatic melanoma tumor-derived cell lines HT-144 and A375 proliferate in both 10% FBS and 1% ITS media, but remain quiescent in 0% FBS medium ( Supplementary Fig.  9a , b). By contrast, the primary melanoma tumor-derived cell line, MEL-JUSO, remains quiescent in both lipid-depleted media (1% ITS and 0% FBS medium) ( Supplementary  Fig. 9c ). We depleted SREBF1 with ASO-4 in several melanoma cell lines cultured under the three media conditions. We found that ASO-4 decreased viability of proliferative and quiescent cells in all conditions ( Supplementary Fig. 9d-i ). Comparing the conditions with growth factors (10% FBS and 1% ITS), we find that lipid availability in the medium somewhat decreases cellular sensitivity to ASO-4 inhibition. We reason that, although the cancer cells are able to utilize ambient lipids 61 , DNFA is required for cell survival regardless of external lipid availability.
We next investigated whether activated DNFA contributes to the mechanism of resistance to BRAF inhibitors (BRAFi, e.g. vemurafenib) observed in melanoma cells harboring the oncogenic BRAF mutation BRAF V600E 62 . We derived two BRAFi-resistant cell lines: HT-144BR from a vemurafenib-sensitive cell line HT-144, and LOXIMVIBR from a vemurafenib-insensitive cell line LOXIMVI, with prolonged vemurafenib treatment (Fig.  4a, Supplementary Fig. 9j ). By testing with ASO-4, we determined that vemurafenibsensitive, vemurafenib-insensitive and vemurafenib-resistant cell lines all depend on SREBP1 for survival ( Fig. 4b and Supplementary Fig. 9k ). We found that DNFA gene expression was higher in vemurafenib-resistant cell lines than in vemurafenib-untreated cell lines ( Fig. 4c and Supplementary Fig. 9l ). To confirm that inhibition of DNFA diminishes cell viability, we then used small molecule inhibitors of DNFA enzymes FASN and SCD, which have been reported to decrease growth of a number of tumor types in preclinical studies [63] [64] [65] , in 10% FBS (lipid-containing) medium. We observed decreased cell viability in both HT-144 and HT-144BR cells (Fig. 4d, f) . The effect was less potent than SREBF1 depletion by ASO-4; however, we observed much stronger effects on cell survival when combining two inhibitors together. Bliss independence analysis 66 confirmed positive synergy between FASN and SCD inhibitors (Fig. 4e, g ). DNFA thus appears vital to the vemurafenib resistance mechanism.
To explore the mechanistic role of DNFA in vemurafenib resistance, we investigated immediate impact of vemurafenib on DNFA gene expression by performing time course assays on HT-144 cells in 1% ITS culture medium. After one-day treatment, vemurafenib exerts low-dose stimulation and high-dose inhibition of DNFA gene expression, exhibiting hormesis 67 (i.e. bell-shaped dose-response curves; Supplementary Fig. 10a-g ). We observed a dose-dependent induction of PPARGC1a expression with vemurafenib treatment (Supplementary Fig. 10h ) as expected, given that the BRAF/MEK pathway directly suppresses PPARGC1a expression and fatty acid oxidation in melanomas 68, 69 . DNFA inhibition in response to high-dose vemurafenib treatment may correlate with onset of cell death, whereas DNFA stimulation at low-dose vemurafenib treatment suggests rapid cellular resistance response. We observed that SREBF1 depletion by ASO-4 abolished the SCD and ASCL1 induction accompanying low-dose vemurafenib treatment (Fig. 4h-j) . This confirms that DNFA stimulation by vemurafenib depends on SREBP1.
Consistently, vemurafenib exerts little induction of DNFA gene expression and no dosedependent induction of PPARGC1a expression in A375 cells ( Supplementary Fig. 11a-h ), a cell line with reported MEK/ERK reactivation associated with vemurafenib treatment 70 . After treatment with an ERK inhibitor together with vemurafenib to achieve complete inhibition of BRAF/MEK/ERK pathway 71 , similarly to current clinical practice 72 , we observed strong induction of DNFA gene expression ( Supplementary Fig. 11i ). Our overall interpretation is that BRAF/MEK/ERK pathway inhibition promotes elevated DNFA gene expression, which then contributes to vemurafenib tolerance in melanoma cells.
Finally, we investigated treatment with ASO-4 in combination with vemurafenib. We found that that ASO-4, whether alone or in combination with vemurafenib, effectively killed HT-144 cells (Fig. 4k ) and A375 cells (Supplementary Fig. 11j ). However, there is a mild antagonistic effect between ASO-4 and vemurafenib at low doses by Bliss analysis (Fig.  4l and Supplementary Fig. 11k ). We regard this as corollary to DNFA stimulation by vemurafenib (Fig. 4h-j and Supplementary Fig. 10a-g ), while noting that, consistent with our findings above for A375, vemurafenib treatment alone yielded little induction of DNFA gene expression in A375 compared to HT-144, and the antagonistic effect was correspondingly lower. In both cell lines, high-dose ASO-4 exerts dominant cell killing effect over vemurafenib in combination treatment.
Discussion
Cancers frequently exhibit reprogrammed metabolic traits such as elevated DNFA 3 that act to sustain active proliferation and cell survival under adverse conditions, and support the process of tumorigenesis and metastasis, as well as resistance to targeted therapies. The diverse genetic paths cancers take to achieve such traits have frustrated efforts to exploit them clinically [73] [74] [75] . Most DNFA enzymes are primarily regulated at the transcriptional level in a coordinated manner 76 , thus mRNA abundance of DNFA genes can be employed as a simple surrogate for DNFA activities. We find that elevated expression of multiple DNFA genes is prevalent in many cancers, suggesting that cancer cells depend upon high DNFA. Our results further show that elevated mRNA expression of DNFA enzymes (e.g. SCD) may serve as a prognostic marker for some cancer types, even though they are not considered oncodrivers. Moreover, the DNFA pathway appears to be linked to malignant cancer cell types independently of cancer-associated onco-drivers including constitutively active BRAF mutants. Our data suggest that elevated DNFA gene expression is intrinsic to malignant cells in melanomas, regardless of proliferative state and oncogenic mutation status. This may be consistent with the notion of increased DNFA as an "oncosustenance" pathway, with well-definable mechanistic contributions to cancer survival and proliferation. Once the oncosustenance pathway becomes active, it may not always matter which oncodrivers acted prior to cancer onset. Indeed, it has already been suggested that malignant cancer cells may have ongoing reliance upon oncogene-induced signaling pathways, but not upon initial onco-drivers 77 . It is also possible that SREBP1 transcription autoregulation 25 might "lock in" elevated DNFA expression in malignant cells., It seems reasonable to suggest that the scope of therapeutic investigations, which frequently focus on mutated oncogenes, could be broadened to include oncosustenance mechanisms.
We demonstrated in melanomas that SREBP1 is sufficient to up-regulate DNFA genes. Inhibition of SREBF1 by ASO treatment results in significant reduction in the expression of DNFA genes, thereby promoting cell death, and the combined effect of multiple individual DNFA enzyme inhibitors is synergistic. Previous studies have shown that SREBP1 binding and RNAP II recruitment to DNFA gene promoters represents the primary mechanism for transcription activation 78, 79 . In accord with this, we observed that RNAP II accumulated at the proximal promoter regions of SCD and FASN. Under lipiddepleted (SREBP1-activating) cell culture condition, we observed two indications of productive transcription elongation. First, there was elevated RNAP II with serine 2 phosphorylation at its C-terminal domain (RNAPII-S2p) 59 at the gene bodies of FASN and SCD. Second, we found an increase in the histone mark for transcription elongation (H3K36me3) 80 at the gene bodies of both genes. Based on these findings, we suggest a refined mechanism for regulation of RNAP II machinery at lipogenic gene promoters as a two-step process: RNAP II recruitment to proximal promoters, followed by RNAP II release for productive elongation. This appears to explain highly active and synchronous DNFA gene expression in melanomas, and perhaps other cell types. It is currently unclear how SREBP1 triggers RNAP II release for productive elongation.
Melanomas are frequently treated with vemurafenib, a targeted therapy to inhibit the oncogenic BRAF pathway. Because it sometimes fails to inhibit MEK/ERK (key targets downstream of BRAF) 81 , current clinical regimens combine inhibitors of both BRAF and MEK for treating metastatic melanomas 72, 82 . However, even when combined inhibition is achieved, resistance arises via genetic alterations that upregulate the PI3K/AKT pathway 83 . We have found that malignant melanoma cells are able to continue (and even increase) DNFA after pro-survival signaling networks are blocked (e.g. with vemurafenib). We suspect that AKT activates SREBP1 and DNFA for survival in BRAFi-resistant melanoma cells, because DNFA gene activation and elevated lipogenesis is a wellcharacterized output of increased PI3K/AKT signaling 84 . Regardless, we find that 1) vemurafenib treatment is associated with DNFA stimulation and 2) activation of DNFA improves viability of some melanoma cell lines both before and after they achieve resistance to combined BRAF and MEK inhibition.
Our determination that SREBP1 is mechanistically important for resistance to targeted therapies dovetails with a similar recent finding 85 , but relies on new evidence. Putting both sets of observations together, it appears that SREBP1 and its downstream DNFA targets are necessary for melanoma cell survival and drug resistance. Our findings suggest that DNFA activity may represent a potential screening tool for the development of novel melanoma therapies.
In summary, our work demonstrates that melanoma engages the DNFA pathway for cell survival and drug resistance, employing activation of SREBP1 to directly promote transcription activation and elongation of DNFA enzyme genes. This raises the intriguing notion of SREBP1 and/or DNFA enzyme inhibition for development of future melanoma therapies.
Methods
Cell culture and reagents. The human melanoma cell lines HT-144, MEL-JUSO, LOXIMVI, WM1552C and MeWo were kindly provided by C. Benes (MGH Center for Molecular Therapeutics). A375 cell line was purchased from American Type Culture Collection (ATCC). Maintained in a humidified incubator at 37 °C with 5% CO2, all cell lines were cultured in RPMI 1640 Medium (21870092, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Gibco), plus 2 mM L-Glutamine (Gibco) and 50 U/ml Penicillin-Streptomycin (Gibco). Two types of lipid-free medium were used for assays: 0% FBS medium contained the RPMI 1640 Medium supplemented with 2 mM LGlutamine (Gibco) and 50 U/ml Penicillin-Streptomycin (Gibco); 1% ITS medium contained the RPMI 1640 Medium supplemented with 1x Insulin-Transferrin-Selenium (ITS-G, Thermo Fisher Scientific), 2 mM L-Glutamine (Gibco) and 50 U/ml PenicillinStreptomycin (Gibco).
The BRAF inhibitor vemurafenib (S1267) and ERK inhibitor SCH772984 (S7101) were purchased from Selleck Chemicals. SCD inhibitor MF-438 (569406, Sigma) and FASN inhibitor GSK 2194069 (5303, Tocris) were dissolved in dimethyl sulfoxide (DMSO) to yield 50 mM stock solutions for in vitro studies. To generate vemurafenib-resistant cells, parental cells were exposed to increasing concentrations of vemurafenib (from 1 μM to 2 μM) for three months. The resistance was confirmed by measuring cell viability under vemurafenib treatment.
TCGA data analysis. We analyzed 10,210 TCGA samples from 30 cancer types, for which RNA-Seq data were publically available. Briefly, gene-level RNA-Seq expression data (normalized RSEM (RNA-seq by expectation-maximization) value) were obtained from cBioportal (http://www.cbioportal.org). For Kaplan-Meier plots, RNA-Seq expression data and patient survival data from TCGA all cancers data set (10,210 samples) or TCGA skin cutaneous melanoma (SKCM) data set (476 samples) were obtained from UCSC Xena (https://xenabrowser.net). To compare the gene expression in normal skin tissues and skin tumors (Fig S2b, c) , we used the uniformly analyzed RNA-Seq expression data of TCGA and GTEx (analyzed by TOIL method
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) from UCSC Xena. The principal component analysis (PCA) in Fig S2c was performed with the R function prcomp. To compare the gene expression with oncogenic mutations in TCGA skin tumor study groups ( Supplementary Fig. 4 ), RNA-Seq and oncogene mutation data were obtained and analyzed using CGDS R package 87 .
Plasmids, siRNAs and ASOs. pcDNA3-Flag-nSREBP1a (plasmid #26801) and pcDNA3-Flag-nSREBP1c (plasmid #26802) were purchased from Addgene 55 . HT-144 cells were transfected with plasmids with Lipofectamine 2000 reagent (Thermo Fisher Scientific). The human-specific siRNAs targeting SREBF1 (6720), SREBF2 (6721), MED15 (51586) and CREBBP (1387) were pre-designed ON-TARGETplus SMARTpool siRNA reagents from Dharmacon. Each ON-TARGETplus SMARTpool siRNA was a mixture of four siRNA duplexes. Sequences of individual siRNAs in each SMARTpool reagent were as follows: siSREBF1-05 (J-006891-05):
5' -GCGCACUGCUGUCCACAAA -3' siSREBF1-06 (J-006891-06):
5' -GAAUAAAUCUGCUGUCUUG -3' siSREBF1-07 (J-006891-07):
5' -CGGAGAAGCUGCCUAUCAA -3' siSREBF1-08 (J-006891-08):
5' -GCAACACAGCAACCAGAAA -3' siSREBF2-05 (J-009549-05): 5' -GGACAGCGCUCUGGCAAAA -3' siSREBF2-06 (J-009549-06):
5' -GCACACUGGUUGAGAUCCA -3' siSREBF2-07 (J-009549-07):
5' -GCAGUGUCCUGUCAUUCGA -3' siSREBF2-08 (J-009549-08):
5' -GAAAGGCGGACAACCCAUA -3' siMed15-09 (J-017015-09): 5' -CCAAGACCCGGGACGAAUA -3' siMed15-10 (J-017015-10):
5' -GGGUGUUGUUAGAGCGUCU -3' siMed15-11 (J-017015-11):
5' -GGUCAGUCAAAUCGAGGAU -3' siMed15-12 (J-017015-12):
5' -CCGGACAAGCACUCGGUCA -3' siCREBBP-06 (J-003477-06): 5' -GCACAGCCGUUUACCAUGA -3' siCREBBP-07 (J-003477-07):
5' -UCACCAACGUGCCAAAUAU -3' siCREBBP-08 (J-003477-08):
5' -GGGAUGAAGUCACGGUUUG -3' siCREBBP-09 (J-003477-09):
5' -AAUAGUAACUCUGGCCAUA -3'
The negative control siRNAs were the ON-TARGETplus Non-Targeting Pool reagents (D-001810-10, Dharmacon). Single-stranded antisense oligonucleotides (ASOs) for SREBP1 were designed and purchased as the locked nucleic acid (LNA) gapmers with phosphorothioate bonds from Exiqon. Sequences of individual ASOs were as follows: ASO-Neg: 5' -+C*+G*+A*A*T*A*G*T*T*A*G*T*A*+G*+C*+G -3' ASO-1: 5' -+G*+C*+G*C*A*A*G*A*C*A*G*C*+A*+G*+A*+T -3' ASO-2:
5' -+T*+A*+A*G*G*G*G*A*G*T*T*A*+A*+C*+G*+G -3' ASO-3:
5' -+T*+A*A*G*G*T*T*T*A*G*A*G*+G*+G*+T*+G -3' ASO-4:
5' -+C*+T*+T*+A*G*G*G*T*C*A*A*G*A*T*+C*+G -3' ASO-5:
5' -+C*+A*+G*C*A*G*A*T*T*T*A*T*+T*+C*+A*+G -3' ASO-6: 5' -+A*+C*+C*+G*T*A*G*A*C*A*A*A*+G*+A*+G*+A -3' + indicates a 2'-O, 4'-C-methylene-linked bicyclic ribonucleoside (LNA). * indicates a phosphorothioate internucleotide linkage.
siRNAs were suspended in RNase-free 1x siRNA Buffer (Dharmacon) to yield 20 µM stock solutions. ASOs were suspended in sterile ddH2O for stock solutions. Melanoma cell lines were transfected with siRNAs or ASOs using Lipofectamine RNAiMAX transfection reagent (Thermo Fisher Scientific) and the reverse transfection protocol suggested by the manufacture. Cells were subjected to immunoblotting or RT-qPCR analyses three days after transfection.
Reverse transcription quantitative PCR (RT-qPCR) and RNA-Seq assays. mRNA was isolated from cultured cells using the RNeasy Mini Kit (Qiagen). RNA was treated with RNase-free DNase (Qiagen). RNA concentrations were quantified with Qubit™ RNA BR Assay Kit (Thermo Fisher Scientific). One μg RNA was used for cDNA synthesis with RNA to cDNA EcoDry™ Premix (TaKaRa) containing both random hexamer and oligo(dT)18 primers (Double Primed). qPCR was carried out in triplicates on a LightCycler® 480 (Roche) using LightCycler® 480 SYBR Green I Master (Roche). qPCR primers were designed by MGH primer bank (https://pga.mgh.harvard.edu/primerbank/) and the primer sequences are listed in table 1. Relative gene expression levels were calculated using the 2 −ΔΔCt method 88 , normalized to the 18S housekeeping gene, and the mean of negative control samples was set to 1.
For RNA-Seq, RNA samples were harvested and treated with RNase-free DNase (Qiagen). RNA quality was verified with the RNA ScreenTape (Agilent) on Agilent 2200 TapeStation (Agilent). mRNAs were isolated from total RNA for RNA library preparation using NEBNext® Poly(A) mRNA Magnetic Isolation Module (NEB). RNA-Seq libraries were generated using NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina® (NEB) and quantified using KAPA Library Quantification Kit (KAPABiosystem). Adaptor indexed strand-specific RNA-Seq libraries were pooled and sequenced using the pairend 75-bp per read setting for NextSeq® 500 High Output v2 Kit (150 cycles) on the NextSeq® 500 sequencer (Illumina)
Immunoblotting assay. Total cell lysate was prepared with RIPA buffer with protease inhibitors (Protease Inhibitor Cocktail Tablets, Roche). Nuclear and cytoplasmic protein fractions were prepared with NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific). Protein samples were separated on the SDS-PAGE gels using 4-15% Mini-PROTEAN® TGX™ Precast Gels (Bio-Rad) and then transferred to polyvinyl difluoride (PVDF) membranes (Immobilon-P, Millipore) for immunoblotting analysis. The following primary antibodies were used: mouse anti-SREBP-1 (IgG-2A4, BD Biosciences), rabbit anti-FASN (C20G5, Cell Signaling), rabbit anti-SCD (23393-1-AP, Proteintech), rabbit anti-ACSL1 (D2H5, Cell Signaling), rabbit anti-ACSS2 (D19C6, Cell Signaling), rabbit anti-histone H3 (9715, Cell Signaling) and rabbit anti-actin (13E5, Cell Signaling). After being incubated with primary antibodies overnight in PBST solution with 5% non-fat dry milk, membranes were probed with HRP-conjugated affinity-purified donkey anti-mouse or anti-rabbit IgG (GE Healthcare) and visualized using the Immobilon Western Chemiluminescent HRP Substrate (Millipore).
RNA-Seq and ChIP-Seq analyses. For RNA-Seq, Illumina sequencing reads (FASTQ files) were checked with FASTQC for quality control and then aligned to the human genome (GRCh38.86). Genome index generation and sequence alignment were performed using STAR software 89 , followed by sorting and indexing of BAM files with SAMtools. Raw counts of reads mapped to genes were calculated using HT-Seq
90
. Differential expression analysis was performed using DESeq2 R package 91 . The KEGG pathway analysis of differentially expressed gene lists and principal component analysis (PCA) were performed using functions within DESeq2.
SREBP1 ChIP-Seq in multiple cancer cell lines were previously published 92 . Bam files of SREBP1 and IgG control ChIP-seq from the same cell lines were downloaded from Encode (https://www.encodeproject.org). SREBP1 binding peaks were called with Modelbased Analysis of ChIP-Seq (MACS) 93 and then annotated with ChIPseeker R package 94 . We performed de novo motif analysis of the SREBP1-binding sites with HOMER software (http://homer.ucsd.edu/homer/). Overlapping genes between RNA-Seq and ChIP-Seq datasets were identified by BioVenn 95 . Pathway annotation network analysis was performed on Cytoscape using ClueGo with REACTOME pathway 96 .
ChIP quantitative PCR (ChIP-qPCR).
For each ChIP assay, 5 × 10 7 cells were used. Chromatins from HT-144 cells were fixed with 1% formaldehyde (Polysciences) and prepared with Magna ChIP™ HiSens Chromatin Immunoprecipitation Kit (EMD Millipore). Nuclei were sonicated on a sonic dismembrator 550 (Thermo Fisher Scientific) with a microtip (model 419) from Misonix Inc. Lysates were sonicated on ice with 10 pulses of 20 sec each (magnitude setting of 3.5) and a 40-sec rest interval. The supernatant was used for immunoprecipitation with the following antibodies: rabbit anti-SREBP1 (H-160, Santa Cruz Biotechnology), rabbit anti-RNA Polymerase II (8WG16, BioLegend), rabbit anti-RNA polymerase II CTD repeat YSPTSPS (phospho S2) antibody (ab5095, Abcam), rabbit anti-RNA polymerase II CTD repeat YSPTSPS (phospho S5) (ab5131, Abcam), rabbit anti-Histone H3 (tri methyl K36) (ab9050, Abcam). qPCR reactions in triplicates were performed on a LightCycler® 480 (Roche) using LightCycler® 480 SYBR Green I Master (Roche). qPCR primers are listed in table 2.
Cell viability assay and synergy score. For dose-response assay, 1,000 -2,000 cells were seeded per well in Falcon™ 96-Well Imaging Microplate with Lid (Corning). Cells were then cultured in the absence or presence of indicated drugs for 4-6 days. Relative cell viability was quantified with the CellTiter-Glo® Luminescent Cell Viability Assay Kit (G7572, Promega) and luminescent signals were measured with the Envision 2103 Multilabel Microplate Reader (Perkin Elmer). Experiments were performed independently for two or three times. Titration curves and IC50 values were generated using GraphPad Prism software. Dose-response data of drug combinations were analyzed with the SynergyFinder R package for synergism 66 . Synergy scores were calculated across all concentration combinations using Loewe or Bliss models.
Code availability. All custom code used during the current study is available upon reasonable request. RT-qPCR assay of mRNA shows relative expression of DNFA enzymes from siRNAs treatment groups to that of negative control siRNA treatment (siNegative). f-h, HT-144 cells were transfected with plasmids carrying the transcriptionally active N-terminal portion of SREBP1a (nSREBP1a), N-terminal portion of SREBP1c (nSREBP1c) or empty vector (pcDNA3) for two days. f, the total cell lysate was analyzed by Western blot assay using the indicated antibodies. g, h, the mRNAs were analyzed with RT-qPCR assay. The bar graphs show the relative expression of DNFA enzymes to that of pcDNA3 (control) transfection group. Data are expressed as mean ± SD and quantified from triplicates. One-way ANOVA tests were performed. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ChIP-qPCR signals were compared between cells cultured in 10% FBS and 1% ITS medium condition. Data were presented as mean ± SD and quantified from 3 triplicates. Two-way ANOVA tests were performed. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. . Data are presented as mean ± SD and quantified from triplicates. One-way ANOVA tests were performed. ns, not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. k, HT-144 cells were transfected with ASO-4, and then treated in combination with vemurafenib. Cell viability was measured by cell titer-glo assay three days after combined treatment in 1% ITS medium. l, the drug interaction in k was evaluated by Bliss independence model. Tables   Table 1 The Table 2 The following primers were used for ChIP-qPCR
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5' -CAGGCTGGGAAACTCACATC -3' SCD 651F
5' -CCGTGAGTTGGGAATGTGGA -3' SCD 651R
5' -TCACATCCCCACGAAGACAA -3' SCD 883F
5' -GGAACTTTTCTCCGTTGCGT -3' SCD 883R
5' -GCCACTCCGCTCTCTAATCA -3' SCD 1006F
5' -CCACGTGTCTCTTCTCCTGA -3' SCD 1006R
5' -TTCCAAGTAGAGGGGCATCG -3' f.
